SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C.  20549

 


 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 


 

Date of Report (Date of earliest event reported):  June 17, 2004

 

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

 

Massachusetts

 

0-17999

 

04-2726691

(State or other
jurisdiction of
incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

128 Sidney Street, Cambridge, MA  02139

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (617) 995-2500

 

 

(Former name or former address, if changed since last report)

 

 



 

Item 5.   Other Events.

 

On June 17, 2004, Joseph J. Villafranca, Ph.D. was appointed to the ImmunoGen, Inc. Board of Directors.  The press release announcing this event is incorporated herein by reference and filed as Exhibit 99.1 hereto.

 

Item 7Financial Statements and Exhibits.

 

 

(c)                                  Exhibits.

 

Exhibit No.

 

Exhibit

 

 

 

99.1

 

Press Release of ImmunoGen, Inc. dated June 22, 2004

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ImmunoGen, Inc.

 

 

(Registrant)

 

 

 

 

Date: June 22, 2004

/s/ Virginia A. Lavery

 

 

Virginia A. Lavery

 

Vice President, Finance and
Treasurer

 

3